27910818|t|Histomorphometric and transcriptome evaluation of early healing bone treated with a novel human particulate dentin powder
27910818|a|Human particulate dentin (HPD) shows potential as an alternative bone grafting material. However, the mechanism of bone healing at the molecular level after grafting with HPD is unclear. This study assessed the histological and global gene expression of bone tissues grafted with HPD. The HPD was prepared to 250-500 Âµm in size. X-ray diffraction (XRD) and energy dispersive x-ray spectroscopy (EDX) were performed to confirm the crystal structure, organic compound residues, and surface morphology, respectively. Bony defects were created on the heads of 24 New Zealand White rabbits. Sterilized HPD was used as the grafting material. The quality and quantity of new bone formation was evaluated using micro-CT and histologic analyses during the 8 week experimental periods. For microarray assay, bone tissue and blood samples were taken at 3, 5 and 7 d post-implantation. The results of XRD and EDX showed that HPD exhibited physical and chemical properties similar to natural hydroxyapatite. New bone formation was observed after HPD implantation compared to the controls, as shown on hematoxylin and eosin staining and micro-CT. The bone volume of HPD treated animals was higher than that of the control group at all observation times. Microarray analysis showed that vascular development coupled with immune and inflammatory related genes were expressed in the early healing stage. The gene coding for the IL-1 antagonist, IL1RN, was expressed to inhibit the inflammatory response, and at the same time, the CCL2 gene was activated to 2.3 times the normal level. BMP2, RUNX2, COL1A, and OPN expression were also up-regulated. CCL2 predominated in osteoblastogenesis of the HPD - treated bony defect in the early stage of healing. HPD accelerated bone regeneration and augmentation. These results suggested that HPD provided potential as a bone graft resource during the bone healing process.
27910818	0	17	Histomorphometric	T059	C0200760
27910818	22	35	transcriptome	T086	C3178810
27910818	36	46	evaluation	T058	C0220825
27910818	56	68	healing bone	T033	C1321023
27910818	69	81	treated with	T061	C0332293
27910818	84	89	novel	T080	C0205314
27910818	90	114	human particulate dentin	T031	C0011429
27910818	115	121	powder	T122	C0032861
27910818	122	146	Human particulate dentin	T031	C0011429
27910818	148	151	HPD	T031	C0011429
27910818	159	168	potential	T080	C3245505
27910818	175	186	alternative	T077	C1523987
27910818	187	200	bone grafting	T061	C0005976
27910818	201	209	material	T122	C0181074
27910818	224	233	mechanism	T169	C0441712
27910818	237	249	bone healing	T033	C1321023
27910818	257	266	molecular	T080	C1521991
27910818	267	272	level	T080	C0441889
27910818	279	287	grafting	T061	C1961139
27910818	293	296	HPD	T031	C0011429
27910818	314	319	study	T062	C2603343
27910818	320	328	assessed	T052	C1516048
27910818	333	345	histological	T169	C0205462
27910818	350	356	global	T080	C2348867
27910818	357	372	gene expression	T045	C0017262
27910818	376	388	bone tissues	T024	C0391978
27910818	389	396	grafted	T169	C0700106
27910818	402	405	HPD	T031	C0011429
27910818	411	414	HPD	T031	C0011429
27910818	419	427	prepared	T033	C4082130
27910818	451	468	X-ray diffraction	T059	C0043301
27910818	470	473	XRD	T059	C0043301
27910818	479	515	energy dispersive x-ray spectroscopy	T059	C2699997
27910818	517	520	EDX	T059	C2699997
27910818	527	536	performed	T169	C0884358
27910818	540	547	confirm	T080	C1456348
27910818	552	569	crystal structure	T104	C0444626
27910818	571	587	organic compound	T109	C0029224
27910818	588	596	residues	T077	C1709915
27910818	602	620	surface morphology	T080	C0332437
27910818	636	640	Bony	T169	C0443157
27910818	641	648	defects	T169	C1457869
27910818	654	661	created	T052	C1706214
27910818	669	674	heads	T029	C0018670
27910818	681	706	New Zealand White rabbits	T015	C0324547
27910818	708	718	Sterilized	T080	C0205556
27910818	719	722	HPD	T031	C0011429
27910818	739	756	grafting material	T122	C0181074
27910818	762	769	quality	T080	C0332306
27910818	774	782	quantity	T081	C1265611
27910818	786	804	new bone formation	T042	C0029433
27910818	809	818	evaluated	T058	C0220825
27910818	825	833	micro-CT	T060	C2350281
27910818	838	848	histologic	T169	C0205462
27910818	849	857	analyses	T062	C0936012
27910818	858	864	during	T079	C0347984
27910818	876	888	experimental	T080	C1517586
27910818	889	896	periods	T079	C1948053
27910818	902	918	microarray assay	T059	C0022885
27910818	920	931	bone tissue	T024	C0391978
27910818	936	949	blood samples	T031	C0178913
27910818	977	994	post-implantation	T079	C1254367
27910818	1000	1007	results	T034	C0456984
27910818	1011	1014	XRD	T059	C0043301
27910818	1019	1022	EDX	T059	C2699997
27910818	1035	1038	HPD	T031	C0011429
27910818	1049	1057	physical	T070	C0597237
27910818	1062	1081	chemical properties	T070	C0243178
27910818	1082	1089	similar	T080	C2348205
27910818	1093	1100	natural	T169	C0205296
27910818	1101	1115	hydroxyapatite	T197	C0020326
27910818	1117	1135	New bone formation	T042	C0029433
27910818	1140	1148	observed	T169	C1441672
27910818	1155	1158	HPD	T031	C0011429
27910818	1159	1171	implantation	T061	C0021107
27910818	1172	1180	compared	T052	C1707455
27910818	1188	1196	controls	T096	C0009932
27910818	1210	1240	hematoxylin and eosin staining	T059	C0523207
27910818	1245	1253	micro-CT	T060	C2350281
27910818	1259	1270	bone volume	T032	C1317149
27910818	1274	1277	HPD	T031	C0011429
27910818	1278	1285	treated	T169	C1522326
27910818	1286	1293	animals	T008	C0003062
27910818	1298	1304	higher	T080	C0205250
27910818	1322	1335	control group	T096	C0009932
27910818	1343	1354	observation	T062	C0302523
27910818	1355	1360	times	T081	C1632851
27910818	1362	1381	Microarray analysis	T059	C1449575
27910818	1394	1414	vascular development	T042	C1621270
27910818	1428	1434	immune	T169	C0439662
27910818	1439	1451	inflammatory	T169	C0333348
27910818	1460	1465	genes	T028	C0017337
27910818	1471	1480	expressed	T045	C0017262
27910818	1488	1493	early	T079	C2363430
27910818	1494	1501	healing	T040	C0043240
27910818	1502	1507	stage	T079	C0205390
27910818	1513	1524	gene coding	T028	C3839127
27910818	1533	1548	IL-1 antagonist	T121	C3536785
27910818	1550	1555	IL1RN	T028	C1416402
27910818	1561	1570	expressed	T045	C0017262
27910818	1574	1581	inhibit	T044	C0021469
27910818	1586	1607	inflammatory response	T046	C1155266
27910818	1635	1644	CCL2 gene	T028	C1337092
27910818	1649	1658	activated	T052	C1879547
27910818	1676	1682	normal	T080	C0205307
27910818	1683	1688	level	T080	C0441889
27910818	1690	1694	BMP2	T028	C1332424
27910818	1696	1701	RUNX2	T028	C1419771
27910818	1703	1708	COL1A	T028	C0017337
27910818	1714	1717	OPN	T028	C1420369
27910818	1718	1728	expression	T045	C0017262
27910818	1739	1751	up-regulated	T044	C0041904
27910818	1753	1757	CCL2	T028	C1337092
27910818	1758	1770	predominated	T080	C0332251
27910818	1774	1792	osteoblastogenesis	T043	C1159974
27910818	1800	1803	HPD	T031	C0011429
27910818	1806	1813	treated	T169	C1522326
27910818	1814	1818	bony	T169	C0443157
27910818	1819	1825	defect	T169	C1457869
27910818	1833	1844	early stage	T079	C2363430
27910818	1848	1855	healing	T040	C0043240
27910818	1857	1860	HPD	T031	C0011429
27910818	1861	1872	accelerated	T169	C0521110
27910818	1873	1890	bone regeneration	T042	C0005972
27910818	1895	1907	augmentation	T033	C0332509
27910818	1915	1922	results	T034	C0456984
27910818	1923	1932	suggested	T078	C1705535
27910818	1938	1941	HPD	T031	C0011429
27910818	1942	1950	provided	T052	C1999230
27910818	1951	1960	potential	T080	C3245505
27910818	1966	1976	bone graft	T061	C0005976
27910818	1977	1985	resource	T078	C0178514
27910818	1986	1992	during	T079	C0347984
27910818	1997	2001	bone	T023	C0262950
27910818	2002	2017	healing process	T040	C2004454